Triple Agonist (GLP-1/GIP/Glucagon) | Advanced Weight Loss & Metabolic Research | For Research Use Only

Retatrutide is a next-generation investigational peptide and one of the most potent triple receptor agonists, targeting GLP-1, GIP, and Glucagon receptors simultaneously. This unique trifecta makes it a powerful tool in obesity, type 2 diabetes, and metabolic syndrome research.

By activating these three key metabolic pathways, Retatrutide has demonstrated unmatched fat-burning effects, significant appetite suppression, and enhanced insulin sensitivity in preclinical and clinical studies—setting a new standard in weight loss peptide research.

🔍 Key Features

• Triple Action: GLP-1 + GIP + Glucagon Receptor Agonist

• Accelerates Fat Loss & Increases Energy Expenditure

• Potent Appetite Suppression & Caloric Intake Reduction

• Improves Glycaemic Control & Insulin Sensitivity

• Outperforms Semaglutide & Tirzepatide in Early Research Models

⚙️ Compound Details

• Compound Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 60mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C in a cool, dry, and dark environment

• Reconstitution: Reconstitute with sterile bacteriostatic water (1–2ml recommended)

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, sunlight, and multiple freeze-thaw cycles

⚠️ For Research Use Only

Retatrutide – 60mg is supplied exclusively for scientific and preclinical research use. It is not intended for human use, therapeutic treatment, or diagnostic purposes.